Discover TD” gamified patient scenarios to help health care professionals accurately diagnose tardive dyskinesia.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, ...

A 28-year-old Middle Eastern man develops severe motor disturbances, including muscle rigidity, tremors, a parkinsonian gait, and involuntary, jerky limb movements, following the administration of a 3 ...

A new study published in the Asian Journal of Psychiatry showed that people of Indian heritage require lower effective ...

Reorganizing its generics business strategy to target 60% instead of 80% of drugs coming off patent and reallocating resources to complex generics will help Teva offset base business erosion and ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

US neuroscience-focused biopharma Neurocrine Biosciences presented new data from more than 300 patients diagnosed with tardive dyskinesia and treated with Ingrezza (valbenazine) capsules at the 2024 ...

Biosciences presented data from more than 300 patients diagnosed with tardive dyskinesia and treated with INGREZZA, or ...

(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) Monday said data from Phase 3 KINECT-3 and KINECT-4 studies showed that treatment with Ingrezza brought holistic improvements over time in patients with ...

IMPACT-TD Registry, the largest study evaluating holistic effects of tardive dyskinesia (TD), highlights that there is a high burden of TD on quality of life regardless of a person’s underlying mental ...

This November marks National Healthy Skin Month, an annual health campaign launched by the American Academy of Dermatology to promote awareness about skin care practices and the importance of reducing ...